Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

No financials disclosed—this is a scheduling notice, not an actionable update.

Risk flags

• ●Lack of financial disclosure is a material risk, as investors have no visibility into revenue, profitability, or cash position. The absence of these figures prevents assessment of financial health or sustainability.
• ●Claims of global partnerships and research relationships are unsupported by contractual details or quantitative evidence, raising uncertainty about the depth and commercial impact of these collaborations.
• ●Forward-looking statements reference ongoing Phase III trials but provide no timelines, enrollment data, or interim results, making it impossible to gauge the likelihood or timing of future approvals or commercial milestones.

Bottom line

This announcement is purely a notice of upcoming interim results and business update events, with no new financial or operational data disclosed. Investors receive a factual overview of approved products, clinical pipeline, and named partnerships, but without supporting numbers or evidence of commercial traction. The lack of financial transparency means there is no basis for equity analysis or investment action at this stage. For this update to become actionable, the company would need to disclose actual financial results, operational metrics, or binding commercial agreements. The key takeaway is that this is an informational scheduling notice, not a substantive update on business performance or outlook.

Announcement summary

(NASDAQ:AAPG; HKEX:6855) Ascentage Pharma Group International announced that it will release its six months 2026 unaudited interim results and provide business updates at 9:00 am Eastern Daylight Time (EDT) on August 19, 2026 / 9:00 pm Hong Kong Time (HKT) on August 19, 2026. The Company will host a Chinese (Mandarin) language investor webcast at 9:00 pm EDT on August 19, 2026 / 9:00 am HKT on August 20, 2026, and an English language investor conference call and webcast at 8:00 am EDT / 8:00 pm HKT on August 20, 2026. Ascentage Pharma's first approved product, Olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs, and is covered by the China National Reimbursement Drug List (NRDL). The Company is conducting FDA- and EMA-cleared registrational Phase III trials for Olverembatinib (POLARIS-2, POLARIS-1, POLARIS-3) and Lisaftoclax (GLORA, GLORA-2, GLORA-3, GLORA-4). Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. Ascentage Pharma has entered into global partnerships with companies such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, and research relationships with Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute, and the University of Michigan. The company projects future developments and their potential effects, but cautions that forward-looking statements are subject to risks and uncertainties.

Disagree with this article?